Berkshire 13F: What to expect from Buffett successor's latest moves

Berkshire Hathaway’s Q2 13F filing (due Friday) is expected to clarify CEO Greg Abel’s reshaping of the conglomerate’s equity portfolio. The update follows a first quarter in which Berkshire became a net buyer of equities for the first time in years, suggesting a potential shift in positioning, though specific trades are not yet disclosed.

Analysis

This is a sentiment event, not a fundamental one: the filing can move BRK.B for a session or two, but the only durable signal is whether capital is being redeployed fast enough to reduce the cash overhang and justify a narrower holdco discount. The market tends to reward evidence that the new regime is proactive, but that reward only persists if the disclosed activity is large enough to matter relative to Berkshire’s balance sheet; small rotations will likely be noise.

The second-order effect is on perception of succession quality. A more active equity book would support the view that capital allocation remains a source of option value under Abel, which can help the multiple even if near-term earnings do not change. Conversely, if the disclosure shows continued caution, that may disappoint traders but actually preserve Berkshire’s firepower for a future dislocation—valuable over 6-18 months, even if it hurts the stock briefly.

The key risk is that 13F data is stale by up to 45 days, so the market may front-run a narrative that has already changed. If the filing shows only marginal movement, the "new era" trade could unwind quickly and BRK.B could lag on a disappointment reset. The contrarian view is that consensus may overstate the need for Abel to prove himself through turnover; Berkshire’s edge is patience, and a low-activity filing could be bullish if it signals discipline rather than inertia.

Key Decisions for Investors

• Do not chase BRK.B into Friday’s filing; treat the 13F as a catalyst only if the disclosed redeployment is large enough to materially reduce cash drag.
• If the filing shows meaningful net equity buying and a lower cash balance, buy BRK.B on any 1-2 day post-release weakness; target 5-8% relative outperformance over the next 1-3 months as the market assigns more credit to Abel’s capital allocation.
• If the filing shows little change or continued net selling, fade any post-print spike in BRK.B by trimming/shorting against strength; thesis is falsified if the next earnings update shows accelerated buybacks or visibly faster deployment of cash.
• Set an alert for any disclosed position changes >$1B-equivalent in a single name or sector; that would be the first tradable clue for second-order winners, but without that scale, this remains a watch item rather than a high-conviction trade.